JP2020524145A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524145A5 JP2020524145A5 JP2019569764A JP2019569764A JP2020524145A5 JP 2020524145 A5 JP2020524145 A5 JP 2020524145A5 JP 2019569764 A JP2019569764 A JP 2019569764A JP 2019569764 A JP2019569764 A JP 2019569764A JP 2020524145 A5 JP2020524145 A5 JP 2020524145A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- disease
- bacterium
- tumor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 241000894006 Bacteria Species 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000002158 endotoxin Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 241000588724 Escherichia coli Species 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521153P | 2017-06-16 | 2017-06-16 | |
| US62/521,153 | 2017-06-16 | ||
| US201862627122P | 2018-02-06 | 2018-02-06 | |
| US62/627,122 | 2018-02-06 | ||
| PCT/US2018/037916 WO2018232353A2 (en) | 2017-06-16 | 2018-06-15 | Bacterial vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524145A JP2020524145A (ja) | 2020-08-13 |
| JP2020524145A5 true JP2020524145A5 (enExample) | 2020-12-10 |
Family
ID=64659967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569764A Withdrawn JP2020524145A (ja) | 2017-06-16 | 2018-06-15 | 細菌性ワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200282037A1 (enExample) |
| EP (1) | EP3638297A4 (enExample) |
| JP (1) | JP2020524145A (enExample) |
| KR (1) | KR20200008058A (enExample) |
| CN (1) | CN111315401A (enExample) |
| AU (1) | AU2018283402A1 (enExample) |
| CA (1) | CA3067370A1 (enExample) |
| WO (1) | WO2018232353A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220362308A1 (en) * | 2019-09-24 | 2022-11-17 | Novome Biotechnologies, Inc. | Oral administration of genetically engineered bacteria |
| US20230236172A1 (en) * | 2020-03-20 | 2023-07-27 | Nantcell, Inc. | T Cells That Respond To Patient Neoepitopes |
| EP4229420A4 (en) * | 2020-10-19 | 2024-10-02 | NantBio, Inc. | NETWORK PEPTIDE NEOEPITOPE GENERATOR |
| CN117757710B (zh) * | 2023-03-16 | 2024-06-04 | 恒敬合创生物医药（浙江）有限公司 | 一种高密度发酵的低内毒素大肠杆菌及其应用 |
| WO2025024603A2 (en) * | 2023-07-25 | 2025-01-30 | Elaine Tsiumas Kaznessis | Personalized bacterial cancer vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004084936A2 (en) * | 2003-02-06 | 2004-10-07 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
| WO2006039701A1 (en) * | 2004-10-01 | 2006-04-13 | University Of South Florida | Flagellin-based adjuvants and vaccines |
| GB0820625D0 (en) * | 2008-11-11 | 2008-12-17 | Lie Tore H | A medicament |
| EP2335730A1 (en) * | 2009-12-18 | 2011-06-22 | Deutsches Krebsforschungszentrum | Fusion polypeptides and their use for prevention and treatment of cancer |
| US20130011424A1 (en) * | 2010-03-09 | 2013-01-10 | Timur ARTEMEV | Polyepitope constructs and methods for their preparation and use |
| EP2941258B1 (en) * | 2013-01-02 | 2019-09-11 | Decoy Biosystems, Inc. | Compositions and methods for treatment of cancer using bacteria |
| WO2018005973A1 (en) * | 2016-06-30 | 2018-01-04 | Nant Holdings Ip, Llc | Nant cancer vaccine |
-
2018
- 2018-06-15 CN CN201880053037.7A patent/CN111315401A/zh not_active Withdrawn
- 2018-06-15 AU AU2018283402A patent/AU2018283402A1/en not_active Abandoned
- 2018-06-15 WO PCT/US2018/037916 patent/WO2018232353A2/en not_active Ceased
- 2018-06-15 KR KR1020207001419A patent/KR20200008058A/ko not_active Ceased
- 2018-06-15 CA CA3067370A patent/CA3067370A1/en not_active Abandoned
- 2018-06-15 US US16/622,900 patent/US20200282037A1/en not_active Abandoned
- 2018-06-15 EP EP18816481.8A patent/EP3638297A4/en not_active Withdrawn
- 2018-06-15 JP JP2019569764A patent/JP2020524145A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524145A5 (enExample) | ||
| JP7036878B2 (ja) | 改変されたヘルパーファージを用いて抗原結合分子を作製する方法 | |
| Martinez-Riano et al. | Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network | |
| Kuraoka et al. | Recall of B cell memory depends on relative locations of prime and boost immunization | |
| JP2025118601A (ja) | がんのネオエピトープ | |
| Palatnik-de-Sousa et al. | Epitope discovery and synthetic vaccine design | |
| JP2013521789A5 (enExample) | ||
| JP2021501572A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| JP2019528077A5 (enExample) | ||
| JP2015519076A5 (enExample) | ||
| Qiu et al. | Listeria monocytogenes: a model pathogen continues to refine our knowledge of the CD8 T cell response | |
| JP2013507970A5 (enExample) | ||
| JP2018512856A5 (enExample) | ||
| JP2012518425A5 (enExample) | ||
| JP2010538618A5 (enExample) | ||
| JP2010536396A5 (enExample) | ||
| JP2014530009A5 (enExample) | ||
| CN118853845A (zh) | 用于对t细胞受体进行测序的系统和方法及其用途 | |
| JP2012523848A5 (enExample) | ||
| IL300841A (en) | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| JP2017538412A5 (enExample) | ||
| SA520420339B1 (ar) | أجسام مضادة مُطعمة ببتيد أذيني مدر للصوديوم |